Yim 2017.
Methods | Randomised clinical trial | |
Participants | Country: South Korea Number randomised: 261 Post‐randomisation dropouts: not stated Revised sample size: 261 Average age: not stated Females: not stated Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or variceal bleeding): not stated Alcohol‐related cirrhosis: not stated Viral‐related cirrhosis: not stated Autoimmune disease‐related cirrhosis (e.g. PSC, PBC, AIH): not stated Other causes for cirrhosis: not stated Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated Follow‐up in months: 0.25 Years of recruitment: 2007‐2016 Exclusion criteria
|
|
Interventions | Participants were randomly assigned to three groups.
Group 1: ciprofloxacin (n = not stated)
Further details: (route and duration not stated)
Group 2: cefotaxime (n = not stated)
Further details: (route and duration not stated) Group 3: ceftriaxone (n = not stated) Further details: (route and duration not stated) Number of participants in each group not stated |
|
Outcomes | None of the outcomes of interest were reported. | |
Notes | Attempts were made to contact the authors in December 2018; there were no replies. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Comment: this information was not available. |
Allocation concealment (selection bias) | Unclear risk | Comment: this information was not available. |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Comment: this information was not available. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Comment: this information was not available. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Comment: this information was not available. |
Selective reporting (reporting bias) | High risk | Comment: a prepublished protocol was not available but the authors do not report routinely measured clinical outcomes adequately. |
Other bias | Low risk | Comment: no other bias was noted. |
AIH: autoimmune hepatitis IV: intravenous PBC: primary biliary cholangitis PSC: primary sclerosing cholangitis SBP: spontaneous bacterial peritonitis